Viatris Inc
Change company Symbol lookup
Select an option...
VTRS Viatris Inc
JGGC Jaguar Global Growth Corporation I
WHG Westwood Holdings Group Inc
BNOX Bionomics Ltd
PSO Pearson PLC
ERNA Eterna Therapeutics Inc
INDP Indaptus Therapeutics Inc
TSLX Sixth Street Specialty Lending Inc
WAVD Wavedancer Inc
SGBX Safe & Green Holdings Corp

Health Care : Pharmaceuticals | Mid Cap Value
Company profile

Viatris Inc. (Viatris) is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of its operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, as well as the Company’s ARV franchise. Its portfolio comprises over 1,400 approved molecules across a range of key therapeutic areas, including key brands and complex generics. It operates around 40 manufacturing sites worldwide, which produce oral solid doses, injectables, complex dosage forms and active pharmaceutical ingredients. Its products include Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen Auto Injector, Fraxiparine and Yupelri.


Last Trade
0.09 (0.92%)
B/A Size

Market Hours

Closing Price
Day's Change
0.22 (2.29%)
Bid close
Ask close
B/A Size
Day's High
Day's Low
(Below Average)

10-day average volume:



All providers
Today's News, September 28, 2023
Viatris (VTRS) Gets FDA Nod for Pupil Dilation Reversal Agent

Viatris (VTRS) and partner Ocuphire Pharma receive FDA approval for Ryzumvi to treat pharmacologically-induced mydriasis of the pupils. (Zacks)

Yesterday's News, September 27, 2023
Viatris and Ocuphire Pharma get FDA green light for eye treatment

Viatris Inc. (VTRS) and Ocuphire Pharma Inc. (OCUP) said Wednesday that the U.S. Food and Drug Administration has approved Ryzumvi to treat the side effects of pharmacologically-induced mydriasis, or dilation of pupils. About 100 million eye...(MarketWatch)

Viatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents

RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024 Viatris Inc. (NASDAQ: VTRS), a global healthcare company, andOcuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on...(PR Newswire)

September 12, 2023
Viatris Named to TIME's World's Best Companies 2023 List

Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to TIME's World's Best Companies 2023 list. This recognition of companies changing the world is presented by TIME, the 99-year-old global media brandand...(PR Newswire)

Nutriband Inc. Receives Five Nominations in the Pharma Industry Awards 2023

Nominations recognize innovative development of AVERSA™ abuse-deterrent transdermal technology ORLANDO, FL / ACCESSWIRE / September 12, 2023 / Nutriband Inc. (the "Company") (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical...(Accesswire)

September 11, 2023
September 07, 2023
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Viatris Inc.

Wilmington, Delaware--(Newsfile Corp. - September 7, 2023) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Viatris Inc. (NASDAQ: VTRS) on behalf of stockholders.(Newsfile)

September 06, 2023
Why Is Viatris (VTRS) Down 4.8% Since Last Earnings Report?

Viatris (VTRS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.(Zacks)

September 05, 2023
Viatris (VTRS) Gets Tentative Approval for HIV Regimen for Kids

Viatris (VTRS) obtains tentative approval from the FDA for a pediatric formulation of abacavir/dolutegravir/lamivudine, a once-daily treatment for children living with HIV.(Zacks)

Viatris Announces U.S. FDA Tentative Approval of a Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), a Once-daily Treatment for Children Living with HIV

Tentative approval will help enhance access to WHO-recommended paediatric regimen with the goal of improved adherence of HIV treatment for children in low- and middle-income countries Viatris Inc.(NASDAQ: VTRS),a global healthcare company, today...(PR Newswire)

August 30, 2023
Viatris (VTRS)'s Technical Outlook is Bright After Key Golden Cross

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?(Zacks)

August 22, 2023
VIATRIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Viatris Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Viatris Inc. (NASDAQ: VTRS) on behalf of long-term stockholders following a class action complaint that was filed against...(BusinessWire)

August 08, 2023
Theravance's (TBPH) Q2 Earnings Beat Estimates, Revenues Miss

Thervance's (TBPH) second-quarter 2023 loss is narrower than expected. Revenues rise year over year.(Zacks)

Company News for Aug 8, 2023

Companies in The News Are: KKR,SAGE,VTRS,FRPT(Zacks)

August 07, 2023
Viatris (VTRS) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.(Zacks)

Viatris (VTRS) Q2 Earnings Beat, Generics Business Grows

Viatris (VTRS) second-quarter earnings and sales beat estimates. The company reiterates its annual guidance. (Zacks)

Viatris (VTRS) Q2 Earnings and Revenues Beat Estimates

Viatris (VTRS) delivered earnings and revenue surprises of 5.63% and 0.80%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?(Zacks)

Viatris Reports Strong Financial and Operational Results for Second Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1]

-- Reports Total Revenues of $3.92 Billion; U.S. GAAP Net Earnings of $264 Million; Adjusted EBITDA of $1.31 Billion; U.S. GAAP Net Cash Provided by Operating Activities of $515 Million; and Free Cash Flow of $447 Million for the Quarter (PR Newswire)

Viatris and Mapi Pharma Announce FDA Acceptance of New Drug Application Filing for GA Depot for the Treatment of Relapsing Forms of Multiple Sclerosis

FDA assigns PDUFA target action date of March 8, 2024 New Drug Application supported by positive Phase III efficacy and safety clinical trial results Milestone builds upon Viatris' long-standing and continued commitment toward addressing the unmet...(PR Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.